Why ENTX lags the market
Up 345% over three years while the S&P 500 rose 80%; up 8% in the past year.
- Free cash flow went from -$12.5M in fiscal 2022 to -$7.5M in fiscal 2025.
The other side, the timeline, and its peers, for Pro members.
Entera Bio (ENTX) stock
$3.24
Quality Score
6
In its industry
#70of 281
Checks firing
8of 14
From 52-week high
-22.9%
ENTX's Quality Score rose 2 points on Tue, Nov 10, to 6. It closed near its high of the day (3 chart checks started).
Follow ENTX's news. Pro members can get an alert when Entera Bio files news, and see its trials, share raises, and its CEO's filings.
Get an alert when ENTX files newsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
NextLate 2026“Phase 3 Initiation Planned for Late 2026: In June 2026, Entera announced that the FDA accepted”
Key facts on ENTX
| Outperforming | Up 159% in 6 months vs the S&P's +2% |
| Latest filing | 8-K, Nov 6 |
1 more reason behind ENTX's 6, free with an account →5 more reasons behind ENTX's 6, for Pro members.
ENTX in the news
ReportExpected to report Friday, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, -3.0% on average. Past reports ›
What's next
Mon Nov 30: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.
1 more date ahead: the meeting, for Pro members.
ENTX catalysts
Coming up
After its last 4 reports it closed -3.0% on average, higher 2 of 4 times.
What's next for ENTX, and how long its cash lasts
Next step the company has named
Late 2026“Phase 3 Initiation Planned for Late 2026: In June 2026, Entera announced that the FDA accepted”
Cash runway
The company says its cash lasts into 2030 (8-K, Aug 7).
Dilution on the horizon
- Shelf registration (S-3, filed May 30, 2025)
- At-the-market share sales program (424B3, filed Jun 6, 2025)
Insiders
Director Geno J Germano bought 20,000 shares on Mar 9. 6 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Why ENTX scores 6
Averagefor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means
- +8Chart checks 8 of 14 firing right now, one point each
- +2Long-term trend above a rising 200-day average
- Run-up adds
- Profit subtracts
- Growth subtracts
- Dilution subtracts
- Volatility subtracts
- Cash flow subtracts
What every line is worth, and the reason behind it, on ENTX and every other stock.Get in free →
How ENTX ranks in Biotech
ENTX is #70 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 70 |
When does ENTX report earnings, and what happens after?
Expected to report Fri Nov 13, after the close (in 3 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What ENTX reported on Nov 6, 2026
The quarter
A profit of $0.11 a share, from $0.07.
“The increase of $3.3 million was primarily attributable to start-up activities for the EB613 Phase 3 program and to activities under the OPKO collaboration.”
Where the sales came from
ENTX's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.
The outlook
No outlook figures read from this release.
In the company's words
“The increase was primarily driven by a $7.5 million non-cash fair value remeasurement of the pre-funded warrants issued in our April 2026 and July 2026 private placements, which were reclassified”
From its results filing (SEC filing · Nov 6)
The numbers
- $520M
- today
- $0
- down 100% on the year
- -$15.8M
- last 12 months
EPS fell 18% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 17% a year over 3 years.
Close after the report, last 3
-10.0%+5.9%+3.5%
May 8Aug 7Nov 6
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 6, 2026 | +1.0% | +3.5% | not yet |
| Aug 7, 2026 | -1.4% | +5.9% | +0.7% |
| May 8, 2026 | -3.9% | -10.0% | -3.1% |
ENTX sales and profit by year
Sales grew in two of the last five years, to $42K in 2025. It lost money in each of the six years.
ENTX has 8 of 14 chart checks firing
The other 10 checks on ENTX, and all 14 on every stock.Get in free →
ENTX RSI today: 61.2, above its 50-day and 200-day averages
RSI 61.2, MACD above signal, above both averages. Not scored.
The deep dive on ENTX
- What it does and how it makes moneyAnnual report, filed Mar 27, 2026
- Where it stands
- What changed in its filingsSEC filing · Mar 27, 2026, against the one of Mar 28, 2025
- Who holds and trades it
ENTX's officers and directors
Officers and directors with a Form 4 in the last 12 months.
About Entera Bio
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
What Entera Bio says it competes with
“The medical and pharmaceutical industries in which we operate are highly competitive and subject to rapid and significant technological change and changes in practice.”
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would move ENTX's score: 8 things
- 8 more filings explained, a plain line each
- Real-time prices, no delay
Straight AnswersStraight Answers
What does ENTX's Quality Score say?
ENTX scores 6 today, which Breakaway calls Average. It is #70 of 281 in Biotech by Quality Score, with 8 of 14 chart checks firing. Up 345% over three years while the S&P 500 rose 80%; up 8% in the past year. Shares: 3.1 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is ENTX's Quality Score?
ENTX scores 6 today, which Breakaway calls Average (6 to 10). That is #70 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ENTX's 6.
When does ENTX report earnings?
Expected to report Fri Nov 13, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ENTX closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.